Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75.

View in: PubMed

subject areas

Adolescent
Adult
Antibodies, Monoclonal
Antineoplastic Agents
Child
Child, Preschool
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Infant
Interleukin-2
Lymphocyte Count
Neuroblastoma
Receptors, Interleukin-2

authors with profiles

Susan L. Cohn